welcome, you, everyone. Thank and Aisha,
put the We have foundation for on company growth. working diligently solid been to
multiple on During progressed fronts. we have the quarter,
to secured refining our a look and recently focus new streamlined we've our additional high level, been capital program private placement, epigenetic insurance life a At financing industry. expanded our strategic have through beyond in the We structure directions.
included know, development epigenetic the our As underwriting our year saliva-based the continued work of the by you in of powered of part science. first half technology
Report, nicely in We of offering, fit life also launched direct-to-consumer with insurers FOXO to which X.X health engagement. wellness our initially we built interest our the and consumer Version Longevity
marketing Through what also this insight work, we that significant guide and but us believe consumers' is steps. on health next gained received interest our feedback, will we into measures
on work However, R&D, and shift these strategic that bioinformatics R&D learnings until work also ensure on and it And successful. are the is demonstrated we can be given AI-powered to we complete offerings direct and our more further refocus development resources to hold additional feel done. prudent our to appropriate and
to right We the intend the believe offerings later return for is disruption, date. is our we these industry ability ] reevaluate to and Life a Insurance at opportunity there, [ to and
coming down the and are Artificial areas unique doubling leveraging in quarters, For Intelligence. of bioinformatics on continued we our expertise strength and R&D
Our businesses services revamped services research. and provides formerly and consulting focused conduct for researchers bioinformatics epigenetics laboratory processing looking on specialized to bioinformatic
part exist XXXX, in the and which labs for data annual analysts data North Independent the pipeline, most market processing only are and suppliers believe are few challenging massive XX%, customers, a of laboratory the a data sense in of with of there at growth positioned. to abound we we the R&D growth in R&D address the much generate amounts And well and billion research America that of share to over has estimated of epigenetics $X rate is market while results. for activities making global solutions top market processing,
steep of eliminate decade software such of nearly to Machine work data. believe open detailed can up service bioinformatic us new the and work future for market a related products, or FOXO. similar expected but to due opportunities Our in epigenetic only the or generate with bioinformatics microarray to analyzing goals to same to will analyzing our this new revenue team learning We worth curve years Learning services Offering has deep experience, and is not allow applying partners bringing experience nuances to new data. who techniques months have
include We to fitness market billion we areas $XXX trillion $X.X a industry; pending billion of reach identified and which capitalization. in to growth expand These $XX R&D development testing, sufficient wellness a and industry; the global industry at-home have estimated into our plan product testing, XXXX. global areas blood
existing future and initial potential strides which partnerships, now making are in our sets believe data We products. conducive identifying in are ramping up
sets, that are far, these position distinct that thus advantage with a us strategic biospecimens we meet partnerships and demands. We the data confident have cultivated to
future measures sets developing new us studies financial with to new to are products market studies. data looking To of planning in in to in in accelerate have organizations multiple maximize we foothold been offer, solidify epigenetics clear requirements our cater our state-of-the-art the sets, the with evolving To equip health, research is and a we measurements we value hurdles versatility the data that discoveries. of the future we beyond tools are This with bring our we be can the of our and will new to and side. Along to direction on clientele. can of entering the services clarity working on number our the hard believe
securities permit this In notes senior issuer amend, senior the sufficient the In solicited the holders a of of we of to we PIK solicited Notes. sufficient the In to consents to a May exchange holders warrant anti-dilution amend. offers. senior purchase amount amount the assumed X we and tender offer, They were in PIK of issuances certain an from Offer prepay without triggering Offer warrants. amend to certain our Note a to the to adjustments permit agreement having PIK Notes, and issuances from warrants consents without PIK Note offer, completed our assumed year, to restate of PIK related exchange amend
in of stock in offer public of approval the conditions May. each the meeting One issuances company A which stockholder common offers, tender first our at tender successfully of obtained the as of we FOXO’s Class was stockholder a annual
removed these several The allowing have. these part impediments to to strategic of our pursue renewed operating as process on offers company more X raising staff expenses have capital raises In favorable would and otherwise the the our of completion we business reduce and thereby of opportunities focus direction. new reduced than to we tender focus,
position learning prospective the has embodies team current company adaptability dedication investors. on and for demonstrated and Our the benefit the elevate of rapid and to our yielding of capabilities
turn to Robbie will would our we We financial provide are committed update. Potashnick, call realize to strategic Robbie? for With like this the successfully a over who to our efforts until corporation. relentless objectives that, continuing I